PI3K-Akt signaling pathway and chemotherapy drug resistance in cancer

Abstract

Abstract:PI3K-Akt signaling pathway plays a critical role in the regulation of cell proliferation, differentiation and apoptosis, and is closely related to the physiological function of cells and thus may cause certain diseases. The excessive activation of this pathway is found closely associated with the formation of drug resistance of tumors. Recent studies in vitro indicate that the combined chemotherapy drugs with PI3K-Akt signaling pathway inhibitors, can significantly enhance the efficiency of chemotherapy drug and lower the value of IC50. Therefore, PI3KAkt signaling pathway has become an important target to inhibit tumor cell growth and reverse tumor drug resistance.

Key words:Signal transduction,Neoplasms,Drug tolerance,Drug therapy

Jiang Penglei, Chang Bingmei. PI3K-Akt signaling pathway and chemotherapy drug resistance in cancer[J]. Journal of International Oncology, 2014, 41(5): 324-327.

References

［1］ Wu K, Chang Q, Lu P, et al. Gefitinib resistance resulted from STAT3mediated Akt activation in lung cancer cells［J］. Oncotarget, 2013, 4(12):2430-2438. ［2］ Boreddy SR, Pramanik KC, Srivastava SK. Pancreatic tumor suppression by benzyl isothiocyanate is associated with inhibition of PI3K/Akt/FOXO pathway［J］. Clin Cancer Res, 2011, 17(7): 1784-1795. ［3］ Cheng X, Xia W, Yang JY, et al. Activation of MDM2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis［J］. Cancer Res, 2010, 70(19): 7684-7689. ［4］ Koti M, Gooding RJ, Nuin P, et al. Identification of the IGF1/PI3K/NFκB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in highgrade serous epithelial ovarian cancer［J］. BMC Cancer, 2013,13:549. ［5］ Zhang HR, Chen JM, Zeng ZY, et al. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI8226 cells via inhibiting PI3K/Akt activity［J］. J Int Med Res, 2013, 41(3):584-595. ［6］ Juengel E, Makarevi′c J, Tsaur I, et al. Resistance after chronic application of the HDACinhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo［J］. PLoS One, 2013, 8(1):1-6. ［7］ He C, Sun XP, Qiao H, et al. Downregulating hypoxiainducible factor2α improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma［J］. Cancer Sci, 2012, 103(3):528-534. ［8］ KilicEren M, Boylu T, Tabor V. Targeting PI3K/Akt represses Hypoxia inducible factor1alpha activation and sensitizes Rhabdomyosarcoma and Ewing′s sarcoma cells for apoptosis［J］. Cancer Cell Int, 2013, 13(1):36. ［9］蔡彦韬, 杨逸, 项建斌, 等. PIK3CA基因与结直肠癌发生发展的研究［J］. 国际肿瘤学杂志, 2012, 39(9):693-696. ［10］ Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy［J］. Clin Cancer Res, 2009, 15(8):2583-2587. ［11］ Chou CH, Lai SL, Chen CN, et al. IL6 regulates Mcl1L expression through the JAK/PI3K/Akt/CREB signaling pathway in hepatocytes: implication of an antiapoptotic role during liver regeneration［J］. PLoS One, 2013, 8(6):e66268. ［12］ Balwani S, Chaudhuri R, Nandi D, et al. Regulation of NFκB activation through a novel PI3Kindependent and PKA/Aktdependent pathway in human umbilical vein endothelial cells［J］. PLoS One, 2012, 7(10):e46528. ［13］ Caporali S, Levati L, Graziani G, et al. NFκB is activated in response to temozolomide in an Aktdependent manner and confers protection against the growth suppressive effect of the drug［J］. J Transl Med, 2012, 10:252. ［14］ Sakamaki J, Daitoku H, Ueno K, et al. Arginine methylation of BCL2 antagonist of cell death (BAD) counteracts its phosphorylation and inactivation by Akt［J］. Proc Natl Sci USA, 2011, 108(15):6085-6090. ［15］ Bleau AM, Hambardzumyan D, Ozawa T, et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stemlike cells［J］. Cell Stem Cell, 2009, 4(3):226-235. ［16］ Kufe DW. Functional targeting of the MUC1 oncogene in human cancers［J］. Cancer Biol Ther, 2009, 8(13):1197-1203. ［17］ Nath S, Daneshvar K, Roy LD, et al. MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes［J］. Oncogenesis, 2013, 2: e51. ［18］ Zielinski R, Przytycki PF, Zheng J, et al. The crosstalk between EGF, IGF, and Insulin cell signaling pathwayscomputational and experimental analysis［J］. BMC Syst Biol, 2009, 3:88. ［19］ Gedaly R, Angulo P, Hundley J, et al. PI103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/Akt/mTOR pathways［J］. Anticancer Res, 2010, 30(12):4951-4958. ［20］ Fang X, Jiang Y, Feng L, et al. Blockade of PI3K/Akt pathway enhances sensitivity of Raji cells to chemotherapy through downregulation of HSP70［J］. Cancer Cell Int, 2013, 13(1):48. ［21］ Gao AM, Ke ZP, Shi F, et al. Chrysin enhances sensitivity of BEL7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway［J］. Chem Biol Interact, 2013, 206(1):100-108. ［22］ Sims JT, Ganguly SS, Bennett H, et al. Imatinib reverses doxorubicin resistance by affecting activation of STAT3dependent NFκB and HSP27/p38/Akt pathways and by inhibiting ABCB1［J］. PLoS One, 2013, 8(1):e55509.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.